Medical use of cannabis for dry eye disease
The clinical value of cannabis in alleviating the symptoms of dry eye disease (DED) is limited at this time due to a lack of clinical evidence.
The Canadian Ophthalmological Society does not support the medical use of cannabis for the treatment of DED or its associated pain symptoms, due to its undesirable side-effects, including dry eye symptoms if smoked, and the absence of scientific evidence showing any beneficial effect at this time.
Other evidence-based, less harmful treatment modalities are available for DED and its associated symptoms.
Read the full position statement and recommendations from the Canadian Ophthalmological Society (COS).
Recommendations from the Canadian Neuro-Ophthalmology Society regarding Neuro-Ophthalmology Care During the COVID-19 Pandemic
May 29, 2020 As we transition into a new normal...
COS – Ophthalmic Surgery Prioritization
Ophthalmic Surgery Prioritization Updated, May 28, 2020 Hospitals and ambulatory...
Checklist on Reopening Ophthalmology Clinics during COVID-19
Checklist on Reopening Ophthalmology Clinics during COVID-19 May 15, 2020...
Can Ophthal Society's Twitter via Twitter Web Client
Redirecting to a Third-Party Website
You are now temporarily leaving the Practice Resource Centre. Clicking the button below will open a third-party website in a new browser tab. The website you are being redirected to is published by a third party and as such, its content is not under the control of the COS.
(If you do not wish to proceed, you can cancel this action by clicking the “X” in the corner of this message window)